symptoms in migraine: A cross-sectional study on 1148 consecutive headache center-based patients.
Dopaminergic symptoms in migraine: A cross-sectional study on 1148 consecutive headache center-based patients - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/32484361/?from_single_result=Dopaminergic
Migraine patients with dopaminergic symptoms are characterized by a full-blown, more disabling migraine. Dopaminergic system modulation should be carefully considered in individuals with migraine with dopaminergic symptoms for both acute...
-
Huma Sheikh, CEO, NY Neurology Medicine, PC4yrThis may help to explain why certain medications are helpful.
Optimal dose of erenumab for preventive treatment of episodic migraine: a systematic review and meta-analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34429056/
Erenumab was effective in patients with episodic migraine. 140 mg erenumab was associated with better efficacy outcomes without increased risk for developing adverse events compared with 70 mg erenumab, and...
-
Huma Sheikh, CEO, NY Neurology Medicine, PC4yrThis is interesting.
'Cochlear Migraine': A Novel Diagnosis
Source : https://www.bc-legal.co.uk/bcdn/634-242-cochlear-migraine-a-novel-diagnosis
A new study has found that those who experience migraines are more likely to develop tinnitus than those who do not. The researchers report that these findings support the newly-proposed...
-
Huma Sheikh, CEO, NY Neurology Medicine, PC4yrI see this frequently along with a pulsating sensation.
Dietary Modification and Migraine Relief
Source : https://link.springer.com/chapter/10.1007/978-3-030-75239-2_11
Kim Hecht Lilian Au Although many medications are currently available in the prevention and treatment of migraines, lifestyle modifications are still recommended to modify symptoms. The role of dietary and...
-
Huma Sheikh, CEO, NY Neurology Medicine, PC4yrThis is a question we get all the time, so helpful to have some guidance.
Pooled retrospective analysis of 70 mg erenumab in episodic and chronic migraine: a two tertiary headache centers experience during clinical practice - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34406609/
Erenumab is a monoclonal antibody, targeted against the calcitonin gene-related peptide (CGRP) receptor. Clinical studies have demonstrated prophylactic efficacy in both episodic (EM) and chronic migraine (CM). The aim of...
-
Huma Sheikh, CEO, NY Neurology Medicine, PC4yrThis confirms other previous studies which is great to see.
-
Migraine Connect4yrKey Points • Conclusion: “This study shows the effectiveness of 70 mg erenumab treatment in previously therapy-refractory migraine patients under real-life conditions at two independent headache centers.” • In this retrospective study, Show More